X-COR Therapeutics, founded in Boston, focuses on developing innovative medical devices for acute respiratory care. Their core mission is to create safer, more affordable CO2 removal solutions using ultra-low-blood flows, making treatment for acute respiratory failure more accessible. The company aims to revolutionize respiratory therapy with their first commercially available CO2 removal device, targeting hospitals and healthcare providers dealing with critical care patients.

Notable figures affiliated with X-COR Therapeutics include co-founder and CEO Steven P. Keller, MD, PhD, a pulmonary and critical care physician at Johns Hopkins Hospital and affiliated faculty at the Harvard-MIT Biomedical Engineering Center. The VP of Engineering, Cameron Jones, PhD, brings extensive research experience from the University of Kentucky. The company's key achievements include advancing the development of their CO2 removal device, which has the potential to significantly impact patient outcomes in intensive care units globally.